Nurix Therapeutics reported its third‑quarter 2025 financial results on October 10, 2025. Revenue for the three months ended August 31, 2025, was $7.9 million, down from $12.6 million in the same period a year earlier. Research and development expenses rose to $86.1 million from $55.5 million, while general and administrative costs increased to $13.2 million from $11.7 million. The company posted a net loss of $86.4 million, or $1.03 per share, compared with a $49.0 million loss ($0.67 per share) in the prior year quarter. Cash, cash equivalents and marketable securities stood at $428.8 million as of August 31, 2025, versus $609.6 million at the end of November 2024.
The announcement also outlined strategic clinical milestones. Nurix plans to initiate pivotal studies for its lead BTK degrader, bexobrutideg, in relapsed/refractory chronic lymphocytic leukemia during the fourth quarter of 2025. In addition, the company presented preclinical data for its IRAK4 degrader, GS‑6791 (NX‑0479), at the EADV 2025 meeting, demonstrating potent pathway inhibition and efficacy in a dermatitis model. These developments underscore the company’s progress in both oncology and autoimmune disease pipelines.
While the company remains well‑capitalized, the sharp increase in R&D and G&A expenses reflects an accelerated build‑out of its clinical programs. Nurix’s cash position of $428.8 million provides a runway of roughly twelve months, but the company will likely require additional financing to support the upcoming pivotal trials and future commercialization efforts. The earnings release confirms the company’s continued focus on advancing its targeted protein degradation platform while highlighting the financial impact of its accelerated development strategy.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.